本周，申万医药生物板块上涨2.89%，沪深300 指数上涨1.68%，医药板块跑赢沪深300 指数1.21%，涨跌幅在申万28 个一级子行业中排名第5 位。六个子板块涨多跌少，其中医疗服务和中药板块涨幅居前，分别上涨6.75%和5.65%；只有前期涨幅较大的生物制品出现下跌，微跌0.32%。截止2020 年9 月1 日，申万医药生物板块剔除负值情况下，整体TTM估值为52.26 倍，相对于剔除银行股后全部A 股的估值溢价率为88.63%。个股涨跌方面（剔除新股），昭衍新药、博腾股份与片仔癀涨幅居前，维康药业、热景生物和昊海生科跌幅居前。

疫情后医药各细分领域头部公司均有不俗的业绩表现，随着政治局会议确立我国以“内循环”为主体，医药消费板块天然具有“内循环”属性，全面凸显配置价值。

行业热点聚焦：1）8 月14 日，CDE 发布新冠疫苗研发指导原则；2）8月20 日，第三批国家组织药品集中采购结果公示；3）8 月26 日，医保局发布《关于建立健全职工基本医疗保险门诊共济保障机制的指导意见（征求意见稿）》。

投资建议：本周医药表现出企稳态势，中报基本披露完毕，二季度疫情相关板块、CXO、零售药店、原料药等板块业绩表现突出，随着国内疫情控制医疗服务、医药消费恢复良好。短期建议继续关注中报业绩表现突出的核心公司。中长期继续推荐高景气细分领域，继续看好检测、疫苗、医疗器械设备和高端耗材、原料药制剂一体化、创新药及其产业链等方向。我们建议关注华兰生物、药明康德、康泰生物、智飞生物、心脉医疗、迈瑞医疗。

本周创业板第一批注册制18 家公司上市，医药板块的“创新”性质将使其长期成为创业板的重要组成部分，我们认为在创业板投资热情高涨，医药估值性价比提升的时点，可以关注创业板带动的板块投资机会；站在后疫情时代和中报期的时点，我们继续关注变化最直接、最快速的医疗器械板块：短期有业绩支撑，疫情后又有基本面变化预期，长期逻辑兑现节奏较快，政策压力整体较小，确定性相对较强；本周中报披露结束，下半年开始，医药板块的主题行情慢慢结束，仍将回归到公司的基本面投资，我们持续关注高景气度、高成长性的优质“赛道”。

Coronavirus belongs to a family that includes viruses causing common cold to middle east respiratory syndrome (MERS), and severe acute respiratory syndrome (SARs), as per the World Health Organization (WHO). The novel coronavirus is a newly discovered strain and is also known as COVID-19 and has led to a rapid rate of respiratory infections and deaths globally. The disease primarily spreads through droplets of saliva or nasal discharge of an infected person, when such a person coughs or sneezes. The common symptoms of the disease are fever, cough, difficulty in breathing, fatigue, loss of smell, tenderness, and muscle pain, among others. The spread of the disease can be avoided through washing hands with soap and water at regular intervals, avoiding contact with those infected, and using a medical facemask. The following figure illustrates the crucial information regarding novel coronavirus spread, its symptoms, susceptibility, and the preventive measures against the disease.

Coronavirus belongs to a family that includes viruses causing common cold to middle east respiratory syndrome (MERS), and severe acute respiratory syndrome (SARs), as per the World Health Organization (WHO). The novel coronavirus is a newly discovered strain and is also known as COVID-19 and has led to a rapid rate of respiratory infections and deaths globally. The disease primarily spreads through droplets of saliva or nasal discharge of an infected person, when such a person coughs or sneezes. The common symptoms of the disease are fever, cough, difficulty in breathing, fatigue, loss of smell, tenderness, and muscle pain, among others. The spread of the disease can be avoided through washing hands with soap and water at regular intervals, avoiding contact with those infected, and using a medical facemask.

The report provides market dynamics and trends related to the VR in healthcare market. In addition, it presents the market estimations and forecast. The study estimates the revenues that are confined to the sales of virtual reality devices used in healthcare facilities. Valuations comprises revenue generated from VR Semiconductor Components, VR Devices, and VR Sensors. However, the market estimates do not include revenue generated from the post-sale services of the devices.

The report provides market dynamics and trends related to the global wound management devices market. In addition, it presents market estimations and forecast. The study estimates the revenue generated from the sales of wound management devices directly from a company and does not include revenue related to wound management services such as consulting and rehabilitation services. The valuations comprise revenue generated from devices, which are used during wound management therapies. However, the report does not include revenue generated by dealers, traders, or brokers of the market during the supply of these devices in hospitals, clinics, and surgery centers. Furthermore, it excludes revenue generated from post-sale services of these devices.

The global tumor genomics market represents the market scenario of the genomic technologies used for detection of various kinds of cancer across the world, taking into considerations of key established companies and their product contributions. The following chapter provides in-depth study of the factors affecting the growth of the tumor genomics market among different geographical regions. Market drivers, challenges or restraints are some of the factors that influence the market growth either by advancing or retarding the growth. Market opportunities are some of the factors for future growth of the market. Apart from these market dynamics, the following sections also describe the regulatory scenario of the global tumor genomics market that includes the approval and launches of various genomic products used for the identification of disease and analyzing the diseases conditions. Furthermore, this section also provides an overview of the competitive landscape that shows the key companies market share and their product offerings in the tumor genomics market. Following these sections, the report also covers the different market segmentation such as products, techniques, applications, end users, and cancer types. In addition, the region chapter enumerates the market scenario of different regions as well as different countries, their market dynamics and market size for each of the regions and countries as well. Furthermore, the company profiling section provides an overview of the key companies, SWOT, financials (for public companies), and their products offerings pertaining to global tumor genomics market